The European Alliance of Associations for Rheumatology (EULAR) has announced a new partnership with Elsevier to publish its scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s online platform, ScienceDirect, beginning January 2025.
“We are delighted that our flagship journal will continue its successful journey with the world's largest publisher and feel that this partnership will equip us ideally for the challenges of the future,” said Professor Daniel Aletaha, EULAR president.
Professor Josef Smolen, ARD editor-in-chief, adds: “Authors, researchers and readers can expect a seamless transition while maintaining the journal's high standards and commitment to excellence.”
Originally published in 1939, the publisher says ARD has always strived for excellence in research advances and novel clinical insights. Thus, it continues to be one of the leading rheumatology journals publishing high-quality scientific papers, original research, reviews, recommendations, viewpoints, and more. Basic, clinical, and translational scientific research across the inflammatory and non-inflammatory musculoskeletal conditions is part and parcel of this spectrum.
The publisher says the journal’s authors, reviewers and editors volunteer their time and expertise to contribute and disseminate this important scientific information to the international research community with a hybrid subscription-based model. Its current (2023) Impact Factor of 20.3 places it second overall in the Rheumatology subject category and first among the journals publishing original research advances, added the publisher. The 2023 CiteScore of 35 places it in the #1/73 (99th percentile) position in the category Medicine/Rheumatology, the publisher continued.
“We are very honoured to be chosen as the publishing partner for EULAR. Elsevier is committed to providing EULAR with a trusted platform, addressing customer needs, and providing insight through data analytics. Our collaboration will further support both organisations’ efforts to improve health outcomes”, stated Carl Schwarz, senior vice president, Health and Medical Sciences at Elsevier.
“ARD is a hugely respected journal in the rheumatology field and will be a great fit with our rheumatology portfolio. We are very proud that EULAR has chosen to partner with us and look forward to helping them and ARD transition to Elsevier,” added Tanya Wheatley, Elsevier’s executive publisher for Rheumatology.
Keep up-to-date with publishing news: sign up here for InPubWeekly, our free weekly e-newsletter.
